EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Boswellic acids as an adjunct therapy in Parkinson’s disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers

Somayyeh Shateri, Seyyed Hossein Khatami, Sajad Ehtiati, Mohammad Reza Talebzadeh, Sadegh Nikakhtar, Monir Hassani Parvar, Seyedeh Ozra Hosseini, Gholamali Shahidi, Amir Hossein Habibi, Farzaneh Salmani, Fatemeh Namvarjah, Ali Riazi und 2 weitere

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01950-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Somayyeh Shateri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. Hauptthemen laut MEDLINE: Parkinson Disease, Triterpenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by postural instability, rigidity, bradykinesia, and resting tremors. Neuroinflammation has been implicated in PD pathogenesis, with inflammatory cytokines serving as potential biomarkers for disease progression and therapeutic monitoring. This study aimed to assess the effects of boswellic acids' supplementation (the main active component of Strowell®) on motor and cognitive function in PD patients, as well as its impact on inflammatory biomarkers. METHODS: In a 6-month, randomized, double-blind, placebo-controlled clinical trial, 58 PD patients were assigned to receive either boswellic acids or a placebo. Clinical assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment (MoCA), with comparisons to baseline scores. Inflammatory biomarkers were measured at baseline and after 1 month. RESULTS: After 6 months, UPDRS scores remained stable in the boswellic acids group but significantly worsened in the placebo group (p = 0.0008). MoCA scores showed a slight but non-significant improvement in the treatment group, while no improvement was observed in the placebo group. In addition, 1 month of boswellic acids' supplementation led to a significant reduction in plasma levels of pro-inflammatory cytokines, including IL-4, IL-1A, IL-12p70, INF-γ, IL-1β, TNF-α, IL-6, and PGE2. CONCLUSION: The findings suggest that boswellic acids' supplementation may help mitigate motor function decline in PD patients while exerting significant anti-inflammatory effects. These results support the potential role of boswellic acids as an adjunctive therapy for Parkinson's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseTriterpenesHumansDouble-Blind MethodMaleFemaleAgedMiddle AgedBiomarkersCytokinesInflammationTreatment Outcome

Stichwörter der Autor:innen

Anti-inflammatoryBoswellic acidsCytokinesNeuroinflammationParkinson’s disease

Substanzen

boswellic acidBiomarkersTriterpenesCytokines

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
  • Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Department of Neurology, School of Medicine, Iranian Center of Neurological Research, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Kondor Pharma Inc., Mississauga, ON, Canada.
  • Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Shateri, S., Khatami, S. H., Ehtiati, S., Talebzadeh, M. R., Nikakhtar, S., Parvar, M. H., Hosseini, S. O., Shahidi, G., Habibi, A. H., Salmani, F., Namvarjah, F., Riazi, A., Tafakhori, A., & Karima, S. (2025). Boswellic acids as an adjunct therapy in Parkinson’s disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01950-4

Vancouver

Shateri S, Khatami SH, Ehtiati S, Talebzadeh MR, Nikakhtar S, Parvar MH, et al. Boswellic acids as an adjunct therapy in Parkinson’s disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01950-4

BibTeX
@article{Shateri2025,
  author = {Shateri, Somayyeh and Khatami, Seyyed Hossein and Ehtiati, Sajad and Talebzadeh, Mohammad Reza and Nikakhtar, Sadegh and Parvar, Monir Hassani and Hosseini, Seyedeh Ozra and Shahidi, Gholamali and Habibi, Amir Hossein and Salmani, Farzaneh and Namvarjah, Fatemeh and Riazi, Ali and Tafakhori, Abbas and Karima, Saeed},
  title = {Boswellic acids as an adjunct therapy in Parkinson’s disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01950-4}
}
Kostenlos starten →